Trustees of Columbia University in the City of New York Buys Shares of 291,828 Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Trustees of Columbia University in the City of New York bought a new stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 291,828 shares of the company’s stock, valued at approximately $417,000. Tenaya Therapeutics comprises 0.1% of Trustees of Columbia University in the City of New York’s portfolio, making the stock its 6th largest position.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. SG Americas Securities LLC boosted its stake in shares of Tenaya Therapeutics by 61.9% during the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock valued at $59,000 after purchasing an additional 15,777 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Tenaya Therapeutics in the fourth quarter worth approximately $45,000. Spire Wealth Management acquired a new position in shares of Tenaya Therapeutics in the fourth quarter worth approximately $53,000. Sei Investments Co. acquired a new position in shares of Tenaya Therapeutics in the fourth quarter worth approximately $100,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Tenaya Therapeutics by 20,670.3% in the fourth quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock worth $7,373,000 after acquiring an additional 5,130,774 shares during the period. Institutional investors own 90.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Morgan Stanley cut their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 12th. Chardan Capital reissued a “buy” rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a research note on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Tenaya Therapeutics in a research report on Friday, April 25th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Stock Up 2.8%

Shares of NASDAQ:TNYA opened at $0.45 on Friday. Tenaya Therapeutics, Inc. has a twelve month low of $0.36 and a twelve month high of $4.65. The stock’s 50 day moving average is $0.52 and its 200-day moving average is $1.31. The firm has a market capitalization of $39.38 million, a price-to-earnings ratio of -0.31 and a beta of 2.99.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). Equities research analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the acquisition, the insider now owns 49,313,559 shares of the company’s stock, valued at $34,519,491.30. This represents a 262.62% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 27,137 shares of company stock worth $13,902. 32.76% of the stock is owned by corporate insiders.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.